Abstract
Previous studies in small series of patients with invasive breast cancer suggested a prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these findings, we performed a retrospective analysis of Ep-CAM expression using a tissue microarray containing tissue specimens from a large patient set. Ep-CAM expression was evaluated by immunohistochemistry in breast cancer tissue from 1715 patients with documented raw survival data. High level Ep-CAM expression (overexpression) was found in 41.7% of tumor samples, low level expression was found in 48.0% and no expression in 10.3% of tumor samples. Ep-CAM expression predicted poor overall survival in this patient cohort (p < 0.0001). Overall survival decreased significantly with increasing Ep-CAM expression. However, in this patient sample Ep-CAM expression was not an independent prognostic marker by multivariate analysis. Subgroup analysis revealed that Ep-CAM expression was a prognostic marker in node-positive (p < 0.0001) but not in node-negative (p= 0.58) breast cancer patients. Intriguingly, Ep-CAM expression was predictive for a dismal prognosis in patients receiving adjuvant cytotoxic (p= 0.03) or hormonal therapy (p < 0.0001) but not in untreated patients (p= 0.41). In summary, this study provides strong evidence that expression of Ep-CAM is a powerful marker of poor prognosis in node-positive invasive breast carcinoma and a potential predictive marker of sensitivity to adjuvant hormonal and/or cytotoxic treatment modalities.
Similar content being viewed by others
References
Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G: The epithelial cell surface antigen 17–1A, a target for antibody–mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38: 47–53, 1986
Linnenbach AJ, Wojcierowski J, Wu SA, Pyrc JJ, Ross AH, Dietzschold B, Speicher D, Koprowski H: Sequence investigation of the major gastrointestinal tumor–associated antigen gene family, GA733. Proc Natl Acad Sci USA 86: 27–31, 1989
Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO: Ep–CAM: a human epithelial antigen is a homophilic cell–cell adhesion molecule. J Cell Biol 125: 437–446, 1994
Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV: The structural analysis of adhesions mediated by Ep–CAM. Exp Cell Res 246: 108–121, 1999
Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A, Ptasznik A, Inverardi L, Ricordi C, Deerinck T, Ellisman M, Reisfeld RA, Hayek A: KSA antigen Ep–CAM mediates cell–cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 140: 1519–1534, 1998
MacDougall JR, Matrisian LM: Targets of extinction: identification of genes whose expression is repressed as a consequence of somatic fusion between cells representing basal and luminal mammary epithelial phenotypes. J Cell Sci 113(Pt3): 409–423, 2000
Trojan A, Tun–Kyi A, Odermatt B, Nestle FO, Stahel RA: Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors. Lung Cancer 36: 151–158, 2002
Herlyn M, Steplewski Z, Herlyn D, Koprowski H: Colorectal carcinoma–specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438–1452, 1979
Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven–year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788–1794, 1998
Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, Lo KM, Lan Y, Super M, Gillies SD, Reisfeld RA: Elimination of established murine colon carcinoma metastases by antibody–interleukin 2 fusion protein therapy. Cancer Res 57: 4948–4955, 1997
Haisma HJ, Pinedo HM, Rijswijk A, der Meulen–Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR, Curiel DT: Tumor–specific gene transfer via an adenoviral vector targeted to the pan–carcinoma antigen EpCAM. Gene Ther 6: 1469–1474, 1999
Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G: Ep–CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981–1982, 2000
Tandon AK, Clark GM, Chamness GC, McGuire WL: Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer. Cancer Res 50: 3317–3321, 1990
Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon–Cardo C: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158: 1245–1251, 2001
Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G: Patterns of her–2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141–1146, 2001
Gillett CE, Springall RJ, Barnes DM, Hanby AM:Multiple tissue core arrays in histopathology research: a validation study. J Pathol 192: 549–553, 2000
Bubendorf L, Nocito A, Moch H, Sauter G: Tissue microarray (TMA) technology: miniaturized pathology archives for highthroughput in situ studies. J Pathol 195: 72–79, 2001
Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5: 1966–1975, 1999
Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE: The expression of Ep–CAM (17–1A) in squamous cell cancers of the lung. Hum Pathol 31: 482–487, 2000
Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ, Warnaar SO: Expression of Ep–CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148: 865–875, 1996
Schon MP, Schon M, Klein CE, Blume U, Bisson S, Orfanos CE: Carcinoma–associated 38–kD membrane glycoprotein MH 99/KS 1/4 is related to proliferation and age of transformed epithelial cell lines. J Invest Dermatol 102: 987–991, 1994 22. de Boer CJ, van Krieken JH, Janssen–van Rhijn CM, Litvinov SV: Expression of Ep–CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 188: 201–206, 1999
Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL: Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin–positive tumor cells in bone marrow. Clin Cancer Res 5: 3999–4004, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spizzo, G., Gastl, G., Obrist, P. et al. High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer. Breast Cancer Res Treat 86, 207–213 (2004). https://doi.org/10.1023/B:BREA.0000036787.59816.01
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000036787.59816.01